Serial Number 87748391
Registration 6583771
700

Registration Progress

Application Filed
Jan 9, 2018
Under Examination
Oct 30, 2018
Approved for Publication
Sep 4, 2018
Published for Opposition
Sep 4, 2018
Registered
Dec 7, 2021

Basic Information

Serial Number
87748391
Registration Number
6583771
Filing Date
January 9, 2018
Registration Date
December 7, 2021
Published for Opposition
September 4, 2018
Drawing Code
2

Status Summary

Current Status
Active
Status Code
700
Status Date
Dec 7, 2021
Registration
Registered
Classes
005 009 042 044

Rights Holder

GRITSTONE BIO, INC.

03
Address
606 Hillside Drive
Jackson, WY 83001

Ownership History

Gritstone Oncology, Inc.

Original Applicant
03
Emeryville, CA

Gritstone Oncology, Inc.

Owner at Publication
03
Emeryville, CA

GRITSTONE BIO, INC.

New Owner After Publication #1
03
EMERYVILLE, CA

GRITSTONE BIO, INC.

Original Registrant
03
Jackson, WY

Legal Representation

Attorney
Shauna M. Wertheim

USPTO Deadlines

Next Renewal Deadline
883 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-12-07)
Due Date
December 07, 2027
Grace Period Ends
June 07, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

50 events
Date Code Type Description
Jun 26, 2025 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 26, 2025 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 26, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 26, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 26, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 7, 2021 R.PR A REGISTERED-PRINCIPAL REGISTER
Nov 3, 2021 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Nov 2, 2021 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Oct 28, 2021 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Oct 26, 2021 IUAF S USE AMENDMENT FILED
Oct 26, 2021 EISU I TEAS STATEMENT OF USE RECEIVED
Jun 23, 2021 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
May 8, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 7, 2021 EX5G S SOU EXTENSION 5 GRANTED
May 7, 2021 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 29, 2021 EXT5 S SOU EXTENSION 5 FILED
Apr 29, 2021 EEXT I SOU TEAS EXTENSION RECEIVED
Oct 16, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 14, 2020 EX4G S SOU EXTENSION 4 GRANTED
Oct 14, 2020 EXT4 S SOU EXTENSION 4 FILED
Oct 14, 2020 EEXT I SOU TEAS EXTENSION RECEIVED
Aug 5, 2020 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 5, 2020 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 5, 2020 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 12, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 10, 2020 EX3G S SOU EXTENSION 3 GRANTED
Mar 10, 2020 EXT3 S SOU EXTENSION 3 FILED
Mar 10, 2020 EEXT I SOU TEAS EXTENSION RECEIVED
Oct 4, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 2, 2019 EEXT I SOU TEAS EXTENSION RECEIVED
Oct 2, 2019 EX2G S SOU EXTENSION 2 GRANTED
Oct 2, 2019 EXT2 S SOU EXTENSION 2 FILED
Mar 27, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 25, 2019 EX1G S SOU EXTENSION 1 GRANTED
Mar 25, 2019 EXT1 S SOU EXTENSION 1 FILED
Mar 25, 2019 EEXT I SOU TEAS EXTENSION RECEIVED
Oct 30, 2018 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 4, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 4, 2018 PUBO A PUBLISHED FOR OPPOSITION
Aug 15, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 28, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 27, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 26, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 26, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 22, 2018 GNRT O NON-FINAL ACTION E-MAILED
Jun 22, 2018 CNRT R NON-FINAL ACTION WRITTEN
Jun 22, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 21, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 20, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 20, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED

Detailed Classifications

Class 005
pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; vaccines; vaccine preparations
First Use Anywhere: Mar 18, 2019
First Use in Commerce: Mar 18, 2019
Class 009
next-generation sequencing (NGS) data processor; bioinformatics data processor; downloadable computer software for genome analysis, developing personal treatment strategies for patients with diagnosed cancer, analyzing, screening, identifying, quantifying, and interpreting data in the field of mass spectrometry
First Use Anywhere: Sep 17, 2016
First Use in Commerce: Sep 17, 2016
Class 042
Providing temporary use of on-line nondownloadable software and applications for genome analysis, developing personal treatment strategies for patients with diagnosed cancer; conducting early evaluations in the field of pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development and evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platforms for manufacturing therapeutics; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer; consulting services for others in the field of design, planning, and implementation of clinical trials; scientific research services, namely, collection of specific molecular and genomic data for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; scientific research services, namely, collection of specific molecular and genomic data for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing scientific advice in the fields of cancer biology, cancer treatment, pharmaceutical side effects, genomics, cancer medicine and translational medicine; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from cancer patients; providing an online, non-downloadable computer software platform for purposes of storing and providing information about an individual's cancer profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice
First Use Anywhere: Sep 17, 2016
First Use in Commerce: Sep 17, 2016
Class 044
healthcare
First Use Anywhere: Mar 18, 2019
First Use in Commerce: Mar 18, 2019

Additional Information

Design Mark
The mark consists of 46 line segments radiating out from a natural sun stone shape design.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005 009 042 044